首页> 美国卫生研究院文献>other >Cardiac Extracellular Matrix-Fibrin Hybrid Scaffolds with Tunable Propertiesfor Cardiovascular Tissue Engineering
【2h】

Cardiac Extracellular Matrix-Fibrin Hybrid Scaffolds with Tunable Propertiesfor Cardiovascular Tissue Engineering

机译:具有可调性质的心肌细胞外基质-纤维蛋白混合支架用于心血管组织工程

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Solubilized cardiac extracellular matrix (ECM) is being developed as an injectable therapeutic that offers promise for promoting cardiac repair. However, the ECM alone forms a hydrogel that is very soft compared to the native myocardium. As both the stiffness and composition of the ECM are important in regulating cell behavior and can have complex synergistic effects, we sought to develop an ECM-based scaffold with tunable biochemical and mechanical properties. We used solubilized rat cardiac ECM from two developmental stages (neonatal, adult) combined with fibrin hydrogels that were crosslinked with transglutaminase. We show that ECM was retained within the gels and Young’s modulus could be tuned to span the range of the developing and mature heart. C-kit+ cardiovascular progenitor cells from pediatric patients with congenital heart defects were seeded into the hybrid gels. Both the elastic modulus and composition of the scaffolds impacted the expression of endothelial and smooth muscle cell genes. Furthermore, we demonstrate that the hybrid gels are injectable, and thus have potential for minimally invasive therapies. ECM-fibrin hybrid scaffolds offer new opportunities for exploiting the effects of both composition and mechanical properties in directing cell behavior for tissue engineering.
机译:可溶性心脏细胞外基质(ECM)被开发为可注射的治疗剂,有望促进心脏修复。但是,与天然心肌相比,单独的ECM会形成非常柔软的水凝胶。由于ECM的刚度和组成在调节细胞行为中很重要,并且可能具有复杂的协同作用,因此我们试图开发一种具有可调节的生化和机械特性的基于ECM的支架。我们使用了来自两个发育阶段(新生儿,成人)的可溶大鼠心脏ECM,并与通过转谷氨酰胺酶交联的纤维蛋白水凝胶结合使用。我们证明ECM被保留在凝胶中,并且可以调整Young的模量以涵盖发育中和成熟心脏的范围。将患有先天性心脏缺陷的小儿患者的C-kit +心血管祖细胞接种到杂交凝胶中。支架的弹性模量和组成都影响内皮和平滑肌细胞基因的表达。此外,我们证明杂化凝胶是可注射的,因此具有微创疗法的潜力。 ECM-纤维蛋白混合支架为组织工程中指导细胞行为的组合物和机械性能的影响提供了新的机会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号